Description
Pre-made Lentivirus express the CAR construct of “3xFLAG-anti-CD22-ScFV (VL-VH)-CD8 hinge-CD28-CD3ζ”. It does not contain any selection marker, trying to minimize the marker’s possible immunogenicity.
This CAR construct, contains the N-term 3xFLAG tagged “ CD22-scFv [VH-(G4S)x4-VL]” recognition domain, linked to CD28 stimulatory domain, expressed under the enhance EF1a promoter. The lentivector’s core structure is represented by the scheme below.
CD22 is a cell surface glycoprotein expressed on B cells. It is involved in B cell activation and regulation. CD22 is a target in CAR-T therapy for B-cell malignancies, especially in cases where CD19-targeted CAR-T cells may face challenges. CD22 CAR-T cells offer an alternative approach in certain B-cell lymphomas and leukemias. This CAR construct assembled the identified anti-human CD22 monoclonal antibodies’ coding sequence (clone m971, 704Y). (see Reference1, Reference2).
see details in Product Manual.
CD28, a transmembrane protein on T cells, provides co-stimulatory signals for T cell activation and proliferation. CD28 costimulatory domains in CARs enhance anti-malignancy efficacy, making it a common choice in CAR design.
CD3ζ (T-cell receptor zeta) is expressed by T cells and NK cells. It together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. CD3-zeta is the most commonly used activation component of CARs. It transmits an activation signal to the T cell after the antigen is bound. It can be coupled with additional co-stimulatory signaling for the complete activation.
Negative Controls: To validate the specificity of the targeted CAR-T killing, you can use the negative control CAR lentivirus: the CAR-ctr6 that has the same lentivector backbone but removed the recognition domain.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1662
